作者:Karl B. Hansen、Jaume Balsells、Spencer Dreher、Yi Hsiao、Michele Kubryk、Michael Palucki、Nelo Rivera、Dietrich Steinhuebel、Joseph D. Armstrong、David Askin、Edward J. J. Grabowski
DOI:10.1021/op0500786
日期:2005.9.1
A new synthesis of sitagliptin (MK-0431), a DPP-IV inhibitor and potential new treatment for type II diabetes, suitable for the preparation of multi-kilogram quantities is presented. The triazolopyrazine fragment of sitagliptin was prepared in 26% yield over four chemical steps using a synthetic strategy similar to the medicinal chemistry synthesis. Key process developments were made in the first step
提出了一种新的西他列汀(MK-0431),DPP-IV抑制剂的合成方法以及适用于制备多千克量的II型糖尿病的潜在新疗法。使用类似于药物化学合成的合成策略,在四个化学步骤中以26%的产率制备了西他列汀的三唑并吡嗪片段。在此序列的第一步中进行了关键工艺开发,即在氯吡嗪中添加了肼,以确保大规模安全运行。西他列汀的β-氨基酸片段是通过不对称还原相应的β-酮酸酯,然后分两步精制为N-苄氧基β-内酰胺来制备的。内酰胺水解,然后直接偶联到三唑哌嗪上,裂解后可得到西他列汀。N-苄氧基与盐形成。在八个步骤中,总产率为52%。